Abstract:

Objective To investigate the situation of Acinetobacter baumannii infection in Department of Neonatology, and observe the curative effect of sulbactam on multidrug-resistant Acinetobacter baumannii (MDRAB) infection. Methods The data of 192 cases of Acinetobacter baumannii infection in Department of Neonatology were retrospectively analysed, and the location of infection and drug resistance were investigated. Meanwhile, the efficacy and safety of ampicillin sulbactam plus cefoperazone sulbactam in treatment of infection were evaluated. Results A total of 9 722 cases were admitted to Department of Neonatology between 2010 and 2012, and Acinetobacter baumannii infection developed in 192 (1.97%), most of which were respiratory infection. Among the 192 cases, 171 (89.0%) were cured, 8 (4.2%) died, and the outcomes were not available in the other 13 (6.8%). Thirty-eight cases of MDRAB infection were treated with ampicillin sulbactam plus cefoperazone sulbactam, the favorable clinical response rate was 65.8% (25/38), and there were 9 cases (23.7%) with no response and 4 cases (10.5%) of death. The levels of blood urea nitrogen, creatinine, aspartate aminotransferase and alanine transaminase were monitored before and after treatment with ampicillin sulbactam plus cefoperazone sulbactam in 31 patients, and no therapy-caused hepatic and renal function damage was found. Conclusion The rate of Acinetobacter baumannii infection increases gradually in Department of Neonatology, with serious drug resistance. The efficacy and safety of ampicillin sulbactam plus cefoperazone sulbactam for treatment of Acinetobacter baumannii infection are acceptable, and further studies are needed.

Key words: Acinetobacter baumannii, neonate, ampicillin sulbactam, cefoperazone sulbactam